In recent years, NCI spending on extramural research has been following the same trajectory as Congressional appropriations for the institute: up, up, up.
In 2007, I was happily working as a newly minted director of the Vanderbilt-Ingram Cancer Center in Nashville and continuing the tradition that Dr. Hal Moses had established in building a world-class cancer center.
John Mendelsohn understood the urgency of moving discoveries out of the laboratory and into patients
The University of Texas MD Anderson Cancer Center, the city of Houston, and the world of oncology have lost a great leader in Dr. John Mendelsohn, who contributed greatly to his institution, his community, and his field of expertise.
John Mendelsohn, president emeritus of MD Anderson Cancer Center and an elder statesman in oncology, died Jan. 7 at his home in Houston. He was 82.
I was heartbroken to learn of the passing of my mentor, colleague, and friend, Waun Ki Hong. Dr. Hong was the quintessential physician scientist who specialized in all aspects of medicine, but most notably patient care, research, and education. This is a devastating loss for the entire oncology community, and especially for all of the patients he cared for and helped.
This week, we lost a cancer research pioneer, and friend and mentor to many in the field, with the sudden death of Waun Ki Hong, M.D., a world-renowned clinical researcher who leaves behind a remarkable legacy.
Waun Ki Hong, M.D., F.A.C.P., D.M.Sc.(Hon.), Head, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, October 22, 2013. For Messenger- First Person.Yesterday, I received a succession of phone calls through the afternoon and evening—from Roy Herbst, chief of medical oncology at the Yale Cancer Center, Marge Foti, president of the American Association for Cancer Research, Patrick Hwu, head of the Division of Cancer Medicine at the MD Anderson Cancer Center (MDACC), and Otis Brawley, professor of oncology at Johns Hopkins University.
FDA has created a framework for evaluating the use of real-world evidence to support additional indications for already approved drugs as well as to satisfy drug post-marketing study requirements.
We thought you might want to see what your colleagues in oncology have been reading. So, we went through our analytics to bring you a list of 25 of The Cancer Letter's most-read stories of 2018.
Amy Abernethy, a thought leader in the field of evidence generation and the development of real-world evidence, was named principal deputy commissioner at FDA.
